Aspergillus isolates from patients with chronic pulmonary aspergillosis mycologically and clinically resistant to azole antifungals are sensitive to Ibrexafungerp (SCY-078)

R. Rautemaa-Richardson1,2, C. Moore1,2, K. Rawson2 , L. Novak-Frazer1,2, D. Angulo3 , S. Barat3 , M.D. Richardson1,2

Author address: 

1Division Of Infection, Immunity And Respiratory Medicine, University of Manchester, Manchester, United Kingdom, 2Mycology Reference Centre, Excellence Center For Medical Mycology (ECMM), Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, United Kingdom, 3Scynexis Inc, New Jersey, United States of America


Objectives: Ibrexafungerp (formerly MK-3118, SCY-078) is a novel and structurally distinct triterpenoid glucan synthase inhibitor whose oral availability and efficacy has already been demonstrated against a wide spectrum of Candida species. Currently the drug is being evaluated for efficacy in invasive and chronic pulmonary aspergillosis. Ibrexafungerp has been shown to be effective in vitro and in vivo against a broad range of Aspergillus species, including drug-resistant strains. In vitro activity is an important efficacy indicator of therapeutic success or failure. The objective of this study was to determine the activity of Ibrexafungerp against a panel of Aspergillus strains isolated from the respiratory tract of patients unresponsive to or failing azole therapy, and which were previously shown to be resistant to one or more azole antifungals (itraconazole, voriconazole, posaconazole and isavuconazole) using the EUCAST E.Def 10.1 standard.

Methods: Patients failing azole therapy for chronic pulmonary aspergillosis were identified in the weekly departmental multi-disciplinary team meetings and their isolates selected for Ibrexafungerp sensitivity testing. Twenty-two Aspergillus fumigatus complex, three A. flavus complex and one A. niger complex strains with varying degrees of resistance to one or more azole antifungals were tested by measuring the minimum effective concentration (MEC) for Ibrexafungerp following the EUCAST E.Def 10.1 standard. Where required, isolates were sequenced (using primers to the internal transcribed spacers (ITS), beta-tubulin (bt) and calmodulin (cal) genes) to identify to the species level.

Results: The Ibrexafungerp MEC range for the 26 Aspergillus spp. isolates was 0.008 to 0.25 mg/l. Isolates that were deemed to be resistant to all azoles had an Ibrexafungerp MEC of 0.015 to 0.25 mg/l. One isolate that was resistant to all azoles and amphotericin B was sensitive to Ibrexafungerp (MEC 0.125 mg/l).

Conclusion: The exquisite in vitro activity of Ibrexafungerp against Aspergillus fumigatus, A. flavus and A. niger isolated from patients with chronic pulmonary aspergillosis suggests that this new compound has potential for treating patients with this condition and similar manifestations of pulmonary aspergillosis.


abstract No: 


Full conference title: 

9th Trends in Medical Mycology Conference 2019
    • TIMM (2019)